selected publications
- Deciphering the Tumor Microenvironment in Prostate Cancer: A Focus on the Stromal Component. Cancers. 2024 Review GET IT
- Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1/2 mutation. Journal of translational medicine. 2024 Academic Article GET IT
- Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study. Clinical genitourinary cancer. 2024 Academic Article GET IT
- Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. NPJ precision oncology. 2024 Academic Article GET IT
- Gene Signature for Predicting Metastasis in Prostate Cancer Using Primary Tumor Expression Profiles. 2024 GET IT
- Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study. Clinical genitourinary cancer. 2024 Academic Article GET IT
- Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clinical genitourinary cancer. 2024 Academic Article GET IT
- Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency. 2024 GET IT
- Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring. Cancers. 2024 Editorial Article GET IT
- Distinct mesenchymal cell states mediate prostate cancer progression. Nature communications. 2024 Academic Article GET IT
- Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer. Journal of translational medicine. 2023 Academic Article GET IT
- Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus. 2023 GET IT
- A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus. Nature communications. 2023 Academic Article GET IT
- Standard Operating Procedures (SOPs) for non-invasive multiple biomarkers detection in an academic setting: A critical review of the literature for the RENOVATE study protocol. Critical reviews in oncology/hematology. 2023 Review GET IT
- Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Therapeutic advances in medical oncology. 2023 Academic Article GET IT
- Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Journal of translational medicine. 2023 Academic Article GET IT
- Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nature communications. 2023 Academic Article GET IT
- Germline variants associated with toxicity to immune checkpoint blockade. Nature medicine. 2022 Academic Article GET IT
- "Stromal cells in prostate cancer pathobiology: friends or foes?". British journal of cancer. 2022 Review GET IT
-
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
Cancer cell.
2022
Academic Article
GET IT
Times cited: 57 - Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine. Cancers. 2022 Review GET IT
- Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes. Clinical genitourinary cancer. 2022 Academic Article GET IT
-
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study.
Annals of oncology : official journal of the European Society for Medical Oncology.
2022
Academic Article
GET IT
Times cited: 21 -
Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors.
Clinical genitourinary cancer.
2022
Academic Article
GET IT
Times cited: 1 -
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022
Academic Article
GET IT
Times cited: 37 -
Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer.
Expert review of molecular diagnostics.
2021
Review
GET IT
Times cited: 6 -
Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.
Lung cancer (Amsterdam, Netherlands).
2021
Academic Article
GET IT
Times cited: 11 -
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
JAMA network open.
2021
Academic Article
GET IT
Times cited: 13 -
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021
Academic Article
GET IT
Times cited: 58 -
Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma.
Clinical genitourinary cancer.
2021
Academic Article
GET IT
Times cited: 13 -
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Nature communications.
2021
Academic Article
GET IT
Times cited: 91 -
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study.
Cancer cell.
2020
Letter
GET IT
Times cited: 51 -
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
European journal of cancer.
2020
Academic Article
GET IT
Times cited: 10 -
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.
Nature medicine.
2020
Academic Article
GET IT
Times cited: 176 -
Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma.
Genetics in medicine : official journal of the American College of Medical Genetics.
2020
Academic Article
GET IT
Times cited: 10 -
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Cancer immunology research.
2020
Academic Article
GET IT
Times cited: 55 -
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 13 -
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 21 -
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 71 -
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma.
Genetics in medicine : official journal of the American College of Medical Genetics.
2019
Academic Article
GET IT
Times cited: 45 -
Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Molecular cancer therapeutics.
2019
Academic Article
GET IT
Times cited: 10 -
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.
Clinical genitourinary cancer.
2018
Academic Article
GET IT
Times cited: 4 -
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer.
Cell.
2018
Academic Article
GET IT
Times cited: 225 -
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.
Oncotarget.
2017
Review
GET IT
Times cited: 73 -
The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome.
BMC cancer.
2016
Academic Article
GET IT
Times cited: 30 -
Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa).
International journal of molecular sciences.
2015
Academic Article
GET IT
Times cited: 25 -
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.
International journal of cancer.
2015
Academic Article
GET IT
Times cited: 10 -
Periostin: a novel prognostic and therapeutic target for genitourinary cancer?.
Clinical genitourinary cancer.
2014
Review
GET IT
Times cited: 32 -
Dihydrotestosterone and bicalutamide do not affect periostin expression in androgen-dependent LNCaP prostate cancer cell lines.
Anticancer research.
2013
Academic Article
GET IT
Times cited: 4 -
Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death.
BMC cancer.
2012
Academic Article
GET IT
Times cited: 43 -
Prognostic value of nuclear matrix protein expression in localized prostate cancer.
Journal of cancer research and clinical oncology.
2012
Academic Article
GET IT
Times cited: 7